How to access clinical trial datasets

Access can be granted to datasets from Novo Nordisk sponsored clinical trials completed after 2001 for product indications approved in both the EU and US, which Novo Nordisk assesses can be effectively de-identified to protect patient anonymity. Researchers can complete searches for trials of interest here.

In order to get access to a specific dataset, researchers must submit their research proposal. In doing so the researcher accepts a number of legal provisions, including without limitation:

  • No attempt to identify or contact research subjects.
  • Use the data only for the purposes described in the research proposal.
  • No dissemination or sharing of the data with any third parties not mentioned in the research proposal.
  • No use of the data for any commercial purposes.
  • Agreement that Novo Nordisk gets a fully paid-up, unrestricted non-exclusive license to any and all inventions that may result from the analysis of Novo Nordisk data.
  • Immediate notification of Novo Nordisk and relevant health authorities of any health or safety concerns that may have arisen from the analysis of Novo Nordisk data.
  • Declaration of the intent to publish findings of scientific and medical importance in relevant peer-reviewed journals.

Before the request is forwarded to the Independent Review Board, the Secretariat supporting the Independent Review Board checks whether all the mandatory elements of the research proposal have been included. The Secretariat also checks whether the request pertains to data from Novo Nordisk sponsored trials completed after 2001 on Novo Nordisk product indications approved in both the EU and US and whether the data is already listed in the Novo Nordisk data sharing system.

If the requested data is not already listed, the Secretariat will conduct an assessment of the practicalities and timelines for granting the access. More information about this is included in the Independent Review Board Charter.

The Independent Review Board assesses all complete requests and approves or rejects the proposal without any interference from Novo Nordisk. For the details of how the Independent Review Board operates, please see the Independent Review Board Charter.

The Independent Review Board meets every quarter, depending on whether any access requests have been received, to discuss and make decisions on access requests submitted until five weeks before the Independent Review Board meeting. The Independent Review Board communicates its final decisions directly to the requesters and to Novo Nordisk.

From an ethical perspective, in order to align with the patient consent under which the data was collected, the analysis must study the medicine or disease Novo Nordisk researched in the original study. In case of approval, Novo Nordisk provides the trial dataset which is de-identified to protect patient anonymity together with the redacted Clinical Study Report, thus enabling the researcher to complete the proposed analysis. The data access is granted within a web-based system that includes a statistical computing environment. Access will be limited to data from the specific trial(s) noted in the request.

The researcher must then complete the study and notify the Independent Review Board Secretariat of any pending publications.

Complete access requests will be listed and their status tracked once the access has been granted.

Send access request

Please note that your request can only be processed if the mandatory elements of the research proposal have been attached.

Mandatory elements to be included in access requests